Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes. - Wikidata - thesis-toulmin - TriplyDB

Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.

Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.

http://www.wikidata.org/entity/Q37162418

about

Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications.

P2860

Q53691502-BB68BB28-9E7F-44CE-9FB3-CAED979F1397 Q53692275-A6F7121C-84FB-4754-9C2E-D011EE5BBE3B

P2860

Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.

http://www.wikidata.org/entity/Q37162418

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bioavailability of two license ...... or quality control programmes.

@en

Bioavailability of two license ...... or quality control programmes.

@nl

type

label

Bioavailability of two license ...... or quality control programmes.

@en

Bioavailability of two license ...... or quality control programmes.

@nl

prefLabel

Bioavailability of two license ...... or quality control programmes.

@en

Bioavailability of two license ...... or quality control programmes.

@nl

P1433

Q37162418-3458BDD1-3AA3-49E7-B782-06BA4BA60D12

P1476

Q37162418-D5AF260B-2C66-4647-AE18-CFFE9A2A2DEC

P2093

Q37162418-103DDD0B-F432-4BEE-8FBE-49E367F8F137

Q37162418-11617476-7983-43B8-B0F8-DB3300CAD15E

Q37162418-436EBB85-0B1D-40BB-B8DF-8B11ECF40D15

Q37162418-80052229-3FDA-43B8-91EC-252CE412C3FF

Q37162418-B330F75D-264B-4826-B26E-80DF558BBCF9

Q37162418-BC841278-9FEE-4076-831B-8D9BC6B402F1

Q37162418-F30DBDA7-9771-4843-9BFC-C276EC4BAD96

Q37162418-FD297326-4CAD-47A4-B076-B998BED55D37

P2860

Q37162418-11EC841C-D67C-4051-856F-921D6BB8F5E4

Q37162418-2E0BECE0-81CD-4DE6-8107-23FC71683CDF

Q37162418-3E09DA66-4D22-4F52-8A7F-0737435EA5BD

Q37162418-45F85E2E-BD32-4587-BA0C-4FE904A22FEC

Q37162418-70ED5E5B-C827-44EF-8614-8D87FF77CA0D

Q37162418-7B532762-0704-41B3-B5A3-26BDB702835E

Q37162418-8765B1D3-148D-49E2-91F9-66F5B8DDE9C8

Q37162418-92258E52-81C5-49CE-AAE8-67F7F003949D

Q37162418-9DA96467-019D-4CBF-94E0-B0119F021CB8

Q37162418-AC51BDE4-06CE-461F-97FA-60E087895AEF

P304

Q37162418-5AB94789-DCBC-48BA-A3FC-DD6D8692FABE

P31

Q37162418-FE606E84-5949-43C7-85B6-189EE6A36ACC

P356

Q37162418-6FDCA763-746A-4D62-AA23-0D1DAA242455

P433

Q37162418-E3C196B0-0DC9-43DE-941A-686A5B8151AD

P478

Q37162418-FAC188D5-F665-4E72-8198-2F909C44020B

P50

Q37162418-14487758-D424-4DCE-8507-ED6C8C2F71E5

Q37162418-6FDA96B0-79EC-4694-8311-2A811E11C4B9

Q37162418-907B077C-4BEB-4FF5-AE73-D142D505587D

Q37162418-C3CD3BD6-9552-4E48-82B6-F986DFD24774

P577

Q37162418-5701706C-6CE7-417F-BED3-26311763613A

P698

Q37162418-C2BB45D9-3A4B-4068-A3C7-AB32F08191DB

P921

Q37162418-66A230E6-E0F6-4746-A1D7-BD993F0A0775

P932

Q37162418-452DCFF7-15EC-4B03-BA11-D0A7EB4379E7

P356

P1433

International Journal of Tuberculosis and Lung Disease

P1476

Bioavailability of two license ...... for quality control programmes

@en

P2093

A Bekker

http://www.w3.org/2001/XMLSchema#string

A C Hesseling

http://www.w3.org/2001/XMLSchema#string

H Hundt

http://www.w3.org/2001/XMLSchema#string

H J Zar

http://www.w3.org/2001/XMLSchema#string

J Winckler

http://www.w3.org/2001/XMLSchema#string

L van der Laan

http://www.w3.org/2001/XMLSchema#string

P Smith

http://www.w3.org/2001/XMLSchema#string

W Smythe

http://www.w3.org/2001/XMLSchema#string

P2860

Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.

The need for better data about counterfeit drugs in developing countries: a proposed standard research methodology tested in Chennai, India.

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.

The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children.

Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis.

Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates.

Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa.

P304

915-919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5588/IJTLD.15.0833

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Annelies Van Rie

Helen McIlleron

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27287644

http://www.w3.org/2001/XMLSchema#string

P921

quality control

P932

4978631

http://www.w3.org/2001/XMLSchema#string